Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in HeFH undergoing apheresis
NCT02326220Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Regeneron Pharmaceuticals. Started Mar 2015; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT02326220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326220.